RAPT rockets 180% on licensing deal, $150M private placement (update)
tupungato/iStock via Getty Images RAPT Therapeutics (NASDAQ:RAPT) stock rallied as much as 180% Monday after the company announced a worldwide licensing deal with China’s Shanghai Jemincare for an allergy drug candidate and a $150M private placement of its stock. RAPT (NASDAQ:RAPT) said it